☰

Zahraa Al-Ahmady - Publications

Affiliations: 
2007-2012 The School of Pharmacy University of London, London, England, United Kingdom 
 2012-2018 University of Manchester, Manchester, England, United Kingdom 
 2019- School of Science & Technology Nottingham Trent University, Nottingham, England, United Kingdom 
Area:
Drug Delivery, Nanomedicine
Website:
https://www.ntu.ac.uk/staff-profiles/science-technology/zahraa-al-ahmady
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Al-Ahmady ZS, Dickie BR, Aldred I, Jasim DA, Barrington J, Haley M, Lemarchand E, Coutts G, Kaur S, Bates J, Curran S, Goddard R, Walker M, Parry-Jones A, Kostarelos K, et al. Selective brain entry of lipid nanoparticles in haemorrhagic stroke is linked to biphasic blood-brain barrier disruption. Theranostics. 12: 4477-4497. PMID 35832077 DOI: 10.7150/thno.72167  0.759
2020 Gallud A, Delaval M, Kinaret P, Marwah VS, Fortino V, Ytterberg J, Zubarev R, Skoog T, Kere J, Correia M, Loeschner K, Al-Ahmady Z, Kostarelos K, Ruiz J, Astruc D, et al. Multiparametric Profiling of Engineered Nanomaterials: Unmasking the Surface Coating Effect. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 7: 2002221. PMID 33240770 DOI: 10.1002/advs.202002221  0.592
2019 Al-Ahmady ZS, Jasim D, Ahmad SS, Wong R, Haley M, Coutts G, Schiessl I, Allan SM, Kostarelos K. Selective Liposomal Transport through Blood Brain Barrier Disruption in Ischemic Stroke Reveals Two Distinct Therapeutic Opportunities. Acs Nano. PMID 31693858 DOI: 10.1021/Acsnano.9B01808  0.744
2019 Al-Ahmady ZS, Donno R, Gennari A, Prestat E, Marotta R, Mironov A, Newman L, Lawrence J, Tirelli N, Ashford MB, Kostarelos K. Enhanced Intra-Liposomal Metallic Nanoparticle Payload Capacity Using Microfluidics Assisted Self-Assembly. Langmuir : the Acs Journal of Surfaces and Colloids. PMID 31478662 DOI: 10.1021/Acs.Langmuir.9B00579  0.768
2019 Hadjidemetriou M, McAdam S, Garner G, Thackeray C, Knight D, Smith D, Al-Ahmady Z, Mazza M, Rogan J, Clamp A, Kostarelos K. Human In Vivo Corona: The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: A Proof-of-Concept Clinical Study (Adv. Mater. 4/2019) Advanced Materials. 31: 1970027. DOI: 10.1002/Adma.201970027  0.746
2018 Hadjidemetriou M, McAdam S, Garner G, Thackeray C, Knight D, Smith D, Al-Ahmady Z, Mazza M, Rogan J, Clamp A, Kostarelos K. The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: A Proof-of-Concept Clinical Study. Advanced Materials (Deerfield Beach, Fla.). e1803335. PMID 30488990 DOI: 10.1002/Adma.201803335  0.794
2018 Hadjidemetriou M, Al-Ahmady Z, Buggio M, Swift J, Kostarelos K. A novel scavenging tool for cancer biomarker discovery based on the blood-circulating nanoparticle protein corona. Biomaterials. 188: 118-129. PMID 30343255 DOI: 10.1016/J.Biomaterials.2018.10.011  0.789
2018 Al-Ahmady ZS, Hadjidemetriou M, Gubbins J, Kostarelos K. Formation of protein corona in vivo affects drug release from temperature-sensitive liposomes. Journal of Controlled Release : Official Journal of the Controlled Release Society. 276: 157-167. PMID 29522832 DOI: 10.1016/J.Jconrel.2018.02.038  0.694
2016 Al-Ahmady Z, Lozano N, Mei KC, Al-Jamal WT, Kostarelos K. Engineering thermosensitive liposome-nanoparticle hybrids loaded with doxorubicin for heat-triggered drug release. International Journal of Pharmaceutics. 514: 133-141. PMID 27863656 DOI: 10.1016/J.Ijpharm.2016.09.009  0.733
2016 Hadjidemetriou M, Al-Ahmady Z, Kostarelos K. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. Nanoscale. 8: 6948-57. PMID 26961355 DOI: 10.1039/C5Nr09158F  0.786
2016 Al-Ahmady Z, Kostarelos K. Chemical Components for the Design of Temperature-Responsive Vesicles as Cancer Therapeutics. Chemical Reviews. 116: 3883-918. PMID 26934630 DOI: 10.1021/Acs.Chemrev.5B00578  0.67
2015 Hadjidemetriou M, Al-Ahmady Z, Mazza M, Collins RF, Dawson K, Kostarelos K. In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles. Acs Nano. 9: 8142-56. PMID 26135229 DOI: 10.1021/Acsnano.5B03300  0.793
2015 Al-Ahmady ZS, Scudamore CL, Kostarelos K. Triggered doxorubicin release in solid tumors from thermosensitive liposome-peptide hybrids: Critical parameters and therapeutic efficacy. International Journal of Cancer. 137: 731-43. PMID 25639452 DOI: 10.1002/Ijc.29430  0.649
2015 Lozano N, Al-Ahmady ZS, Beziere NS, Ntziachristos V, Kostarelos K. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent. International Journal of Pharmaceutics. 482: 2-10. PMID 25445515 DOI: 10.1016/J.Ijpharm.2014.10.045  0.759
2014 Al-Ahmady ZS, Chaloin O, Kostarelos K. Monoclonal antibody-targeted, temperature-sensitive liposomes: in vivo tumor chemotherapeutics in combination with mild hyperthermia. Journal of Controlled Release : Official Journal of the Controlled Release Society. 196: 332-43. PMID 25456832 DOI: 10.1016/J.Jconrel.2014.10.013  0.638
2012 Al-Ahmady ZS, Al-Jamal WT, Bossche JV, Bui TT, Drake AF, Mason AJ, Kostarelos K. Lipid-peptide vesicle nanoscale hybrids for triggered drug release by mild hyperthermia in vitro and in vivo. Acs Nano. 6: 9335-46. PMID 22857653 DOI: 10.1021/Nn302148P  0.742
2012 Al-Jamal WT, Al-Ahmady ZS, Kostarelos K. Pharmacokinetics & tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia. Biomaterials. 33: 4608-17. PMID 22459195 DOI: 10.1016/J.Biomaterials.2012.03.018  0.757
Show low-probability matches.